Science moves forward in careful steps. These highlights are peer-reviewed (or large platform trials) and many involve public/NIH funding, but most still need replication, longer follow-up or phase-3 confirmation. The through-line this week: practical wins (home blood pressure care, RSV vaccine benefits) alongside bold ideas (diet-plus-therapy for Glioblastoma, immune-evasive cell therapies, and LSD to treat anxiety). Steady investment in NIH-funded, peer-reviewed research keeps these pipelines flowing—and keeps people healthier.
🧠 Air pollution signal in Lewy body dementia
What’s new: Using 56.5 million US health records plus mouse experiments, long-term PM2.5 exposure was tied to higher LBD risk and α-synuclein–linked neurodegeneration.
Why it matters: Strengthens the case that clean air is brain-health policy and highlights therapeutic pathways.
Journal: Science, Sept 4, 2025.
🩸 Type 1 diabetes: lab-grown islets restore insulin production
What’s new: Phase 1–2 FORWARD (VX-880): stem-cell–derived, fully differentiated pancreatic islets restored endogenous insulin secretion and sharply reduced insulin needs under standard immunosuppression.
Why it matters: Early but credible step toward insulin independence for some people with T1D.
Journal: New England Journal of Medicine, Sept 4, 2025 (issue).
🧂 Artificial sweeteners linked to faster cognitive decline
What’s new: In 12,772 Brazilian adults over ~8 years, higher intake of several low/no-calorie sweeteners (aspartame, saccharin, acesulfame-K, erythritol, sorbitol, xylitol) was associated with faster global cognitive decline—strongest under age 60; no link ≥60.
Why it matters: Observational, but adds weight to moderation recommendations in midlife, especially with diabetes.
Journal: Neurology, Sept 3, 2025.
🩺 Blood-pressure care that meets people where they live
What’s new: In rural South Africa, a home-based hypertension program led by community health workers (with remote nurses) lowered systolic BP and improved control vs usual care.
Why it matters: A practical blueprint for underserved areas: bring care to patients, not just patients to clinics.
Journal: NEJM, Sept 1, 2025.
👁️ Safety watch: certain antibiotics tied to rare intracranial hypertension
What’s new: Systematic review/meta-analysis finds associations between some antibiotics and drug-induced intracranial hypertension (rare but vision-threatening).
Why it matters: Awareness helps clinicians catch symptoms early during prolonged courses.
Journal: Eye (Nature), Sept 5, 2025.
🧠 Brain cancer’s “amino-acid addiction” (and how to exploit it)
What’s new: Many glioblastomas import serine instead of making it; in mice, serine/glycine-restricted diets slowed tumor growth and boosted chemo-radiation. Human tumor tracer studies mapped the fuel switch.
Why it matters: Points to a testable diet-plus-therapy combo and biomarkers to pick the right patients.
Journal: Nature, Sept 3, 2025.
💉 RSV vaccine for older adults: fewer cardio-respiratory hospitalizations
What’s new: In a randomized trial of >131,000 adults ≥60, RSVpreF reduced all-cause cardiorespiratory hospitalizations vs no vaccine; Cardiovascular-only outcomes were not significant.
Why it matters: Adds real-world-scale evidence that RSV shots can help keep high-risk older adults out of the hospital.
Journal: JAMA, online Aug 30, 2025
🧬 “Cocaine-gated” ion channels blunt drug seeking (rats)
What’s new: Protein-engineered ion channels that open only with cocaine rewired lateral habenula circuits to reduce cocaine self-administration without affecting normal reward.
Why it matters: Striking proof-of-concept for drug-specific chemogenetics in addiction (very early, animal work).
Journal: Nature, Sept 3, 2025.
🧫 Marburg virus disease in Rwanda (2024): lessons from rapid control
What’s new: Clinical and epidemiologic report details case identification, lab confirmation, contact tracing, and cross-border coordination in Rwanda’s 2024 Marburg response.
Why it matters: Concrete playbook for containing high-fatality hemorrhagic fevers.
Journal: NEJM, Sept 11, 2025.
🧪 One-time LSD dose eased generalized anxiety (phase 2b RCT)
What’s new: MM120 (LSD) single-dose reduced anxiety in adults with Generalized Anxiety Disorder through 12 weeks; 100 μg looked optimal.
Why it matters: Signals that drug-only psychedelic therapy might help when standard meds fall short (needs phase 3).
Journal: JAMA, Sept 4, 2025.
Stay Curious,
Science Rabbit Team
Leave a Reply